For: | Ghosh S, Ghosh R. Glargine-300: An updated literature review on randomized controlled trials and real-world studies. World J Diabetes 2020; 11(4): 100-114 [PMID: 32313609 DOI: 10.4239/wjd.v11.i4.100] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v11/i4/100.htm |
Number | Citing Articles |
1 |
E. V. Biryukova, M. V. Shinkin, O. M. Mikheeva. Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety. Meditsinskiy sovet = Medical Council 2021; (12): 246 doi: 10.21518/2079-701X-2021-12-246-255
|
2 |
Hernando Vargas-Uricoechea, Pablo Aschner. Comparative efficacy and safety of basal insulins: A review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2021; 15(6): 102318 doi: 10.1016/j.dsx.2021.102318
|
3 |
KM Prasanna Kumar, Subhankar Chowdhury, Ganapathi Bantwal, A G Unnikrishnan, Sanjay Kalra, Sameer Aggarwal, Awadhesh Kumar Singh, Kaushik Pandit, Rishi Shukla, Vijay Vishwanathan, Kunal Khobragade, Prashant S Sarda. Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine. Cureus 2024; doi: 10.7759/cureus.60983
|
4 |
Dudi Hardianto, Efrida Martius, Fahroziah Assyifa, Dihan Laziba, Uli J. Nasution, Fransiska C. Sekaringtyas, Juwartina I. Royani. Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022). 2023; : 814 doi: 10.2991/978-94-6463-112-8_74
|
5 |
Mohammed Hassanein, Walid Al Dahi, Husain Taha Radhi, Abdulraouf AIMahfouz, Juma Al Kaabi, Abdulmuhsen Alshammari, Abdullah Alfutaisi, Mussa H. AlMalki, Rayaz Malik. Expert-Group Practical Advice on Insulin Initiation and Titration for Patients with Type 2 Diabetes in the Gulf Region. Dubai Diabetes and Endocrinology Journal 2022; 28(2): 45 doi: 10.1159/000521437
|
6 |
Pablo Repetto, Daria Ayago. Clinical impact after implementing an insulin protocol involving a switch to insulin glargine 300 U/ml as basal insulin for inpatient glycaemic control: A retrospective single-centre study. Journal of Diabetes and its Complications 2023; 37(9): 108584 doi: 10.1016/j.jdiacomp.2023.108584
|
7 |
Sanjay K. Shah, Mridul Bera, Guru Prasad Bhattacharya, Shambo Samrat Samajdar, Shatavisa Mukherjee. Real-world Clinical Effectiveness on Glycaemic Parameters, Safety and Additional Benefits of Glargine U300 (Toujeo®) Initiation after Oral Antidiabetic Drug Failure in Insulin-naïve Patients with type 2 Diabetes Mellitus. Indian Journal of Endocrinology and Metabolism 2023; 27(5): 426 doi: 10.4103/ijem.ijem_57_23
|
8 |
Didac Mauricio, Pierre Gourdy, Riccardo C. Bonadonna, Nick Freemantle, Gregory Bigot, Celine Mauquoi, Alice Ciocca, Mireille Bonnemaire, Dirk Müller-Wieland. Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis. Diabetes Therapy 2021; 12(4): 1159 doi: 10.1007/s13300-021-01031-z
|
9 |
D Hardianto, E Martius, T Rostinawati, A Safarrida, J I Royani, D Laziba, F Assyifa. Detection of recombinant Pichia pastoris producing glargine. IOP Conference Series: Earth and Environmental Science 2023; 1271(1): 012089 doi: 10.1088/1755-1315/1271/1/012089
|
10 |
Manoj Chawla, Sunil M. Jain, Jothydev Kesavadev, Brij M. Makkar, Vijay Viswanathan, Mangesh Tiwaskar, Aravind R. Sosale, Vijay Negalur, Kirtikumar D. Modi, Mukulesh Gupta, Surinder Kumar, Santosh Ramakrishnan, Nilakshi Deka, Nirmalya Roy. Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel. Diabetes Therapy 2021; 12(1): 133 doi: 10.1007/s13300-020-00979-8
|
11 |
Banshi Saboo, Hemraj Chandalia, Sujoy Ghosh, Jothydev Kesavadev, IPS Kochar, KM Prasannakumar, Archana Sarda, Ganapathi Bantwal, RN Mehrotra, Madhukar Rai. Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials
and Real-world Evidence Across Two Decades. Current Diabetes Reviews 2024; 20(1) doi: 10.2174/1573399819666230310150905
|
12 |
Soumyabrata Roy Chaudhuri, Anirban Majumder, Debmalya Sanya. An initial look form eastern India into the efficacy and safety of glargine U 300-the new ultra long basal insulin. Journal of Diabetes, Metabolic Disorders & Control 2021; 8(1): 1 doi: 10.15406/jdmdc.2021.08.00215
|
13 |
Dirk Müller-Wieland, Nick Freemantle, Riccardo C. Bonadonna, Celine Mauquoi, Gregory Bigot, Mireille Bonnemaire, Pierre Gourdy, Didac Mauricio. Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database. Diabetes Therapy 2023; 14(2): 401 doi: 10.1007/s13300-022-01356-3
|
14 |
Pierre Gourdy, Riccardo C. Bonadonna, Didac Mauricio, Dirk Müller‐Wieland, Celine Mauquoi, Carine Vera, Mireille Bonnemaire, Nick Freemantle. Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis. Diabetes, Obesity and Metabolism 2025; 27(1): 228 doi: 10.1111/dom.16008
|